Identification of chemical compounds regulating PD‐L1 by introducing HiBiT‐tagged cells
Open Access
- 20 January 2021
- journal article
- research article
- Published by Wiley in FEBS Letters
- Vol. 595 (5), 563-576
- https://doi.org/10.1002/1873-3468.14032
Abstract
Programmed death‐ligand 1 (PD‐L1) is a co‐inhibitory molecule expressed on tumor cells. Immune checkpoint inhibitors focusing on the PD‐L1 mechanism are now being studied for the treatment of various cancer types. However, the regulatory mechanism of PD‐L1 is yet to be fully clarified, and a high‐throughput system for comparing the abilities of small compounds in regulating PD‐L1 has not yet been established. Therefore, we created a HiBiT‐tagged lung adenocarcinoma cell line, PC9‐KI, for easier and faster detection of changes in PD‐L1 protein expression. Using PC9‐KI cells, we screened 1280 chemical compounds from the Library of Pharmacologically Active Compounds and identified microtubule polymerization inhibitors and thapsigargin as PD‐L1 upregulators and a p97 inhibitor as a PD‐L1 downregulator.Funding Information
- Japan Society for the Promotion of Science (18K19603, 20H05696)
- Foundation for the National Institutes of Health (AR050631)
- Japan Agency for Medical Research and Development (JP20gm0810008)
This publication has 33 references indexed in Scilit:
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in MelanomaClinical Cancer Research, 2014
- Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasomeNature Immunology, 2013
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K InhibitionClinical Cancer Research, 2013
- Structure–Activity Relationship Study Reveals ML240 and ML241 as Potent and Selective Inhibitors of p97 ATPaseChemMedChem, 2013
- CD8+ T Cells: Foot Soldiers of the Immune SystemImmunity, 2011
- Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathwaysProceedings of the National Academy of Sciences of the United States of America, 2011
- Colchicine in clinical medicine. A guide for internistsEuropean Journal of Internal Medicine, 2010
- The PD‐1 pathway in tolerance and autoimmunityImmunological Reviews, 2010
- Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)Proceedings of the National Academy of Sciences of the United States of America, 2008
- Phase III Study of Second-Line Chemotherapy for Advanced Non–Small-Cell Lung Cancer With Weekly Compared With 3-Weekly DocetaxelJournal of Clinical Oncology, 2005